Skip to main content
main-content

Connective tissue diseases

Systemic lupus erythematosus

29-05-2020 | COVID-19 | News

Elevated rates of COVID-19 respiratory complications in people with rheumatic diseases

People with rheumatic diseases have a significantly higher risk for developing severe COVID-19 respiratory complications than those without, suggest findings from a US cohort study.

28-05-2020 | Systemic lupus erythematosus | News

Lupus therapies may not impact COVID-19 outcomes

Two case series of patients with systemic lupus erythematosus and SARS-CoV-2 infection explore the association between baseline use of lupus medications and COVID-19 outcomes.

22-05-2020 | COVID-19 | News

Rheumatic disease patients ‘not over-represented’ in severe COVID-19 cohort

The prevalence of rheumatic diseases is low among patients admitted to the intensive care unit with severe COVID-19, researchers report.

18-05-2020 | COVID-19 | News

Corticosteroid use may be a risk factor for COVID-19 hospitalization in rheumatic disease patients

Study results from the COVID-19 Global Rheumatology Alliance suggest that corticosteroid use at moderate-to-high doses may be associated with an increased risk for hospitalization among people with rheumatic diseases and SARS-CoV-2 infection.

My lupus patient wants to get pregnant: What next?

Ana Rita Cruz-Machado and Laura Andreoli present a case study of a female patient with systemic lupus erythematosus on treatment with teratogenic immunosuppressive drugs who wanted to have a child.

14-05-2020 | Pregnancy | Case study | Article

My lupus patient wants to get pregnant: What next?

Ana Rita Cruz-Machado and Laura Andreoli present a case study of a female patient with systemic lupus erythematosus on treatment with teratogenic immunosuppressive drugs who wanted to have a child.

13-05-2020 | Systemic lupus erythematosus | News

Hydroxychloroquine use does not protect against severe COVID-19 in people with lupus

Data from the COVID-19 Global Rheumatology Alliance provide further evidence against a protective effect of hydroxychloroquine on the development of severe COVID-19 in patients with systemic lupus erythematosus.

01-05-2020 | Systemic lupus erythematosus | News

Disease characteristics predict belimumab response in SLE

High disease activity, short disease duration, and low baseline damage are associated with an increased response to belimumab in patients with systemic lupus erythematosus, real world study data show.

29-04-2020 | Systemic lupus erythematosus | News

Hydroxychloroquine ‘does not seem to prevent COVID-19’ in people with lupus

The authors of a French case series report the clinical experiences of 17 patients with systemic lupus erythematosus undergoing long-term treatment with hydroxychloroquine who developed COVID-19.

27-04-2020 | COVID-19 | News

COVID-19: FDA warns against chloroquine, hydroxychloroquine use outside specific settings

The US FDA has issued a safety alert warning that chloroquine and hydroxychloroquine for COVID-19 should not be used outside of hospital settings or clinical trials due to an elevated risk for heart rhythm problems with the agents.

24-04-2020 | COVID-19 | News

Rheumatologists, patients report healthcare changes during COVID-19 pandemic

Findings from two questionnaire studies suggest that a substantial proportion of rheumatology patients have experienced changes to their disease management since the emergence of COVID-19.

20-04-2020 | COVID-19 | News

First data from the COVID-19 Global Rheumatology Alliance released

The COVID-19 Global Rheumatology Alliance has released preliminary data on 110 individuals with rheumatic disease and comorbid COVID-19.

16-04-2020 | Systemic lupus erythematosus | News

SLE flares less likely in pregnancy if disease quiescent at conception

The risk for flares during and after pregnancy is low and the severity typically mild in women who have inactive or stable systemic lupus erythematosus in early pregnancy, show data from the PROMISSE study.

08-04-2020 | COVID-19 | News

ACR advises on resource allocation during COVID-19 pandemic

The ACR has issued guiding principles for the allocation of hydroxychloroquine, IL-1 and 6 antagonists, JAK inhibitors, and eculizumab during the COVID-19 pandemic.

07-04-2020 | Lupus nephritis | News

EULAR, ERA–EDTA issue guidelines for managing lupus nephritis

EULAR and the Renal Association–European Dialysis and Transplant Association have issued updated recommendations for the management of lupus nephritis.

07-04-2020 | Systemic lupus erythematosus | Feature | Article

In pursuit of new lupus therapies: The importance of trial endpoints

Eric Morand explores the reasons why the TULIP-1 and TULIP-2 trials of anifrolumab found different primary results, and discusses the search for optimal endpoints in lupus trials.

Rheumatologists urge caution on chloroquine, hydroxychloroquine use for COVID-19

Rheumatologists highlight that more research needs to be carried out before chloroquine and hydroxychloroquine can be recommended for the treatment of COVID-19, and emphasize the need for adequate supplies of these agents for people with rheumatic diseases.

03-04-2020 | COVID-19 | Highlight | News

Rheumatologists urge caution on chloroquine, hydroxychloroquine use for COVID-19

Rheumatologists highlight that more research needs to be carried out before chloroquine and hydroxychloroquine can be recommended for the treatment of COVID-19, and emphasize the need for adequate supplies of these agents for people with rheumatic diseases.

19-03-2020 | Risk prediction | News

Predictors of mortality risk identified in rheumatology patients admitted to the ICU

A number of factors, including the need for mechanical ventilation, central nervous system involvement, and length of stay, are significant predictors for mortality risk among rheumatology patients admitted to intensive care units, researchers report.

10-03-2020 | Systemic lupus erythematosus | News

Treat-to-target endpoints ‘feasible’ in lupus trials

The treat-to-target endpoints of low disease activity, Lupus Low Disease Activity State, and remission are robust outcome measures for clinical trials in systemic lupus erythematosus, researchers report.

Image Credits